FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914093604> ?p ?o ?g. }

• W2914093604 endingPage "844" @default.
• W2914093604 startingPage "833" @default.
• W2914093604 abstract "Objective: To synthesize data on the pharmacokinetics and safety of dolutegravir and elvitegravir in pregnant women living with HIV. Data Sources: A PubMed, EMBASE, Web of Science, and Google Scholar literature search (January 2010 to December 2018) was performed using the search terms dolutegravir, elvitegravir, women, pregnant*, and HIV. Additional reports were identified from conference abstracts and review of reference lists. Study Selection and Data Extraction: English-language studies reporting pharmacokinetic and/or safety data in pregnant women receiving dolutegravir or elvitegravir/cobicistat were included. Data Synthesis: A total of 17 studies were selected. Studies demonstrated a modest decrease in dolutegravir concentrations in pregnancy. Preliminary data suggest an increased risk of neural tube defects when dolutegravir is used at the time of conception. Available pharmacokinetic data in pregnant women showed significantly reduced plasma concentrations of elvitegravir/cobicistat which may increase the risk of virological failure. Current guidelines recommend that dolutegravir should not be initiated in women who have the potential to become pregnant or women in their first trimester of pregnancy and elvitegravir/cobicistat should be avoided during pregnancy. Relevance to Patient Care and Clinical Practice: This review highlights pharmacokinetic and safety data for dolutegravir and elvitegravir/cobicistat in pregnant women. Clinicians need to be aware of these data to convey the risks and benefits of using these agents in women of child-bearing potential. Conclusions: Changes in guideline recommendations reflect emerging data regarding the use of dolutegravir and elvitegravir/cobicistat in pregnancy. Until further information is available, raltegravir or other first-line agents are recommended for women with HIV planning to become pregnant." @default.
• W2914093604 created "2019-02-21" @default.
• W2914093604 creator A5025257865 @default.
• W2914093604 creator A5042069245 @default.
• W2914093604 creator A5071031864 @default.
• W2914093604 date "2019-02-10" @default.
• W2914093604 modified "2023-09-24" @default.
• W2914093604 title "Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV" @default.
• W2914093604 cites W1851689772 @default.
• W2914093604 cites W2014673451 @default.
• W2914093604 cites W2020610488 @default.
• W2914093604 cites W2085120686 @default.
• W2914093604 cites W2085405111 @default.
• W2914093604 cites W2088672808 @default.
• W2914093604 cites W2118872556 @default.
• W2914093604 cites W2155327584 @default.
• W2914093604 cites W2164637230 @default.
• W2914093604 cites W2314718629 @default.
• W2914093604 cites W2403529429 @default.
• W2914093604 cites W2416289930 @default.
• W2914093604 cites W2422955030 @default.
• W2914093604 cites W2615380358 @default.
• W2914093604 cites W2786157050 @default.
• W2914093604 cites W2789831831 @default.
• W2914093604 cites W2789992229 @default.
• W2914093604 cites W2808929367 @default.
• W2914093604 cites W2811505616 @default.
• W2914093604 cites W2883284210 @default.
• W2914093604 cites W2888034043 @default.
• W2914093604 cites W2905422944 @default.
• W2914093604 cites W2915372808 @default.
• W2914093604 doi "https://doi.org/10.1177/1060028019830788" @default.
• W2914093604 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30739498" @default.
• W2914093604 hasPublicationYear "2019" @default.
• W2914093604 type Work @default.
• W2914093604 sameAs 2914093604 @default.
• W2914093604 citedByCount "12" @default.
• W2914093604 countsByYear W29140936042019 @default.
• W2914093604 countsByYear W29140936042020 @default.
• W2914093604 countsByYear W29140936042021 @default.
• W2914093604 countsByYear W29140936042022 @default.
• W2914093604 countsByYear W29140936042023 @default.
• W2914093604 crossrefType "journal-article" @default.
• W2914093604 hasAuthorship W2914093604A5025257865 @default.
• W2914093604 hasAuthorship W2914093604A5042069245 @default.
• W2914093604 hasAuthorship W2914093604A5071031864 @default.
• W2914093604 hasConcept C142462285 @default.
• W2914093604 hasConcept C159047783 @default.
• W2914093604 hasConcept C2777068322 @default.
• W2914093604 hasConcept C2779502633 @default.
• W2914093604 hasConcept C2780524789 @default.
• W2914093604 hasConcept C2993143319 @default.
• W2914093604 hasConcept C3013748606 @default.
• W2914093604 hasConcept C71924100 @default.
• W2914093604 hasConceptScore W2914093604C142462285 @default.
• W2914093604 hasConceptScore W2914093604C159047783 @default.
• W2914093604 hasConceptScore W2914093604C2777068322 @default.
• W2914093604 hasConceptScore W2914093604C2779502633 @default.
• W2914093604 hasConceptScore W2914093604C2780524789 @default.
• W2914093604 hasConceptScore W2914093604C2993143319 @default.
• W2914093604 hasConceptScore W2914093604C3013748606 @default.
• W2914093604 hasConceptScore W2914093604C71924100 @default.
• W2914093604 hasIssue "8" @default.
• W2914093604 hasLocation W29140936041 @default.
• W2914093604 hasOpenAccess W2914093604 @default.
• W2914093604 hasPrimaryLocation W29140936041 @default.
• W2914093604 hasRelatedWork W1557841390 @default.
• W2914093604 hasRelatedWork W2020610488 @default.
• W2914093604 hasRelatedWork W2214609651 @default.
• W2914093604 hasRelatedWork W2405600680 @default.
• W2914093604 hasRelatedWork W2406931452 @default.
• W2914093604 hasRelatedWork W2900893105 @default.
• W2914093604 hasRelatedWork W2906129695 @default.
• W2914093604 hasRelatedWork W2913317838 @default.
• W2914093604 hasRelatedWork W2914093604 @default.
• W2914093604 hasRelatedWork W3027280232 @default.
• W2914093604 hasVolume "53" @default.
• W2914093604 isParatext "false" @default.
• W2914093604 isRetracted "false" @default.
• W2914093604 magId "2914093604" @default.
• W2914093604 workType "article" @default.